77 related articles for article (PubMed ID: 9400021)
1. Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs.
Uhlig S; Featherstone RL; Held HD; Nüsing R; Schudt C; Wendel A
J Pharmacol Exp Ther; 1997 Dec; 283(3):1453-9. PubMed ID: 9400021
[TBL] [Abstract][Full Text] [Related]
2. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ
J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibitors prevent endothelin-1-induced vasoconstriction, bronchoconstriction, and thromboxane release in perfused rat lung.
Held HD; Wendel A; Uhlig S
Biochem Biophys Res Commun; 1997 Feb; 231(1):22-5. PubMed ID: 9070212
[TBL] [Abstract][Full Text] [Related]
4. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
[TBL] [Abstract][Full Text] [Related]
5. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
6. Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.
Schudt C; Winder S; Eltze M; Kilian U; Beume R
Agents Actions Suppl; 1991; 34():379-402. PubMed ID: 1665311
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of IgE-mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors.
Kleine-Tebbe J; Wicht L; Gagné H; Friese A; Schunack W; Schudt C; Kunkel G
Agents Actions; 1992 Jul; 36(3-4):200-6. PubMed ID: 1382373
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs.
Howell RE; Sickels BD; Woeppel SL
J Pharmacol Exp Ther; 1993 Feb; 264(2):609-15. PubMed ID: 8437112
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
[TBL] [Abstract][Full Text] [Related]
12. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors.
Rabe KF; Tenor H; Dent G; Schudt C; Nakashima M; Magnussen H
Am J Physiol; 1994 May; 266(5 Pt 1):L536-43. PubMed ID: 7515580
[TBL] [Abstract][Full Text] [Related]
13. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
Schermuly RT; Roehl A; Weissmann N; Ghofrani HA; Schudt C; Tenor H; Grimminger F; Seeger W; Walmrath D
J Pharmacol Exp Ther; 2000 Feb; 292(2):512-20. PubMed ID: 10640287
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2-dependent bronchoconstriction in perfused rat lungs exposed to endotoxin.
Uhlig S; Nüsing R; von Bethmann A; Featherstone RL; Klein T; Brasch F; Müller KM; Ullrich V; Wendel A
Mol Med; 1996 May; 2(3):373-83. PubMed ID: 8784790
[TBL] [Abstract][Full Text] [Related]
15. Guinea-pig lung adenylyl and guanylyl cyclase and PDE activities associated with airway hyper- and hypo-reactivity following LPS inhalation.
Toward TJ; Nials AT; Johnson FJ
Life Sci; 2005 Jan; 76(9):997-1011. PubMed ID: 15607329
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
[TBL] [Abstract][Full Text] [Related]
17. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
18. Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea pigs: effect of rolipram and dexamethasone.
Toward TJ; Broadley KJ
J Pharmacol Exp Ther; 2001 Jul; 298(1):298-306. PubMed ID: 11408555
[TBL] [Abstract][Full Text] [Related]
19. Adenosine activating A(2A)-receptors coupled to adenylate cyclase/cyclic AMP pathway downregulates nicotinic autoreceptor function at the rat myenteric nerve terminals.
Duarte-Araújo M; Timóteo MA; Correia-de-Sá P
Neurochem Int; 2004 Oct; 45(5):641-51. PubMed ID: 15234106
[TBL] [Abstract][Full Text] [Related]
20. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
Schade FU; Schudt C
Eur J Pharmacol; 1993 Jan; 230(1):9-14. PubMed ID: 8381357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
